- Previous Close
110.50 - Open
111.30 - Bid 112.60 x --
- Ask 114.90 x --
- Day's Range
110.90 - 114.70 - 52 Week Range
88.05 - 120.10 - Volume
2,818 - Avg. Volume
48,066 - Market Cap (intraday)
14.242B - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
35.00 - EPS (TTM)
3.25 - Earnings Date May 15, 2025
- Forward Dividend & Yield 0.85 (0.98%)
- Ex-Dividend Date Jun 6, 2023
- 1y Target Est
--
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
www.biomerieux.com12,557
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 0RUG.IL
View MorePerformance Overview: 0RUG.IL
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0RUG.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0RUG.IL
View MoreValuation Measures
Market Cap
12.94B
Enterprise Value
12.98B
Trailing P/E
30.36
Forward P/E
24.39
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.30
Price/Book (mrq)
3.10
Enterprise Value/Revenue
3.26
Enterprise Value/EBITDA
14.46
Financial Highlights
Profitability and Income Statement
Profit Margin
10.43%
Return on Assets (ttm)
7.23%
Return on Equity (ttm)
9.87%
Revenue (ttm)
3.7B
Net Income Avi to Common (ttm)
385.9M
Diluted EPS (ttm)
3.25
Balance Sheet and Cash Flow
Total Cash (mrq)
423M
Total Debt/Equity (mrq)
13.48%
Levered Free Cash Flow (ttm)
167.89M